Madrigal Pharmaceuticals (NASDAQ:MDGL) Insider Carole Huntsman Sells 419 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 419 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $180,982.86. Following the transaction, the insider owned 12,692 shares of the company’s stock, valued at approximately $5,482,182.48. The trade was a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Carole Huntsman also recently made the following trade(s):

• On Monday, January 26th, Carole Huntsman sold 910 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $493.78, for a total transaction of $449,339.80.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL traded down $6.51 on Friday, hitting $432.83. 440,127 shares of the company were exchanged, compared to its average volume of 374,182. The company’s 50 day moving average price is $492.64 and its two-hundred day moving average price is $486.72. The firm has a market capitalization of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The firm had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. During the same period last year, the business earned ($2.71) earnings per share. The firm’s quarterly revenue was up 210.8% compared to the same quarter last year. Research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC grew its stake in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 66 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at approximately $29,000. Mather Group LLC. acquired a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter worth approximately $33,000. Global Retirement Partners LLC grew its position in Madrigal Pharmaceuticals by 221.7% during the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 51 shares during the last quarter. Finally, First Horizon Corp acquired a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $34,000. 98.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MDGL. B. Riley Financial raised their price objective on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Bank of America cut their price target on shares of Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. UBS Group set a $900.00 target price on Madrigal Pharmaceuticals in a report on Friday, December 19th. Finally, HC Wainwright raised their target price on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $685.31.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.